Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sodium oxybate (Alcover) for reduction of heavy drinking and maintenance of abstinence in alcohol use disorder
2023-506990-37-00Phase 3Authorised
- Sponsor
- Laboratorio Farmaceutico CT
- Start
- Sep 2023
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised trial in alcohol use disorder (AUD) comparing Alcover (sodium oxybate) arm with Placebo arm (2 arms). Primary endpoint: Reduction in heavy drinking days at 3 months. Planned start Sep 2023; status: authorised.
02
Drugs
sodium oxybate
03
Conditions
alcohol use disorder (AUD)
Beyond the preview
Go deeper on 2023-506990-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506990-37-00.